Working Committee for Hospital Epidemiology and Infection Control, University of São Paulo School of Medicine Hospital das Clínicas, São Paulo, Brazil.
Department of Infectious Diseases, University of São Paulo School of Medicine Hospital das Clínicas, São Paulo, Brazil.
J Glob Antimicrob Resist. 2020 Dec;23:352-358. doi: 10.1016/j.jgar.2020.10.013. Epub 2020 Nov 10.
Recurrent urinary tract infections (rUTIs) occur frequently after kidney transplantation (KT), however their optimal management remains undefined. This study aimed to identify risk factors for rUTI and to validate a protocol for UTI and rUTI treatment after KT.
This retrospective cohort study involved patients undergoing KT between January 2013 and July 2016. Patients were followed-up from day of KT until graft loss, death or end of follow-up (31 December 2018). We analysed all episodes of symptomatic UTI. The main outcome measure was rUTI after KT. Analysis was done per episode in a multilevel approach; patient features were considered in the distal level and UTI features in the proximal level. Univariate and multivariate analyses were performed by Cox regression. A propensity score was used to adjust the risk of patients with carbapenem-resistant Enterobacteriaceae.
During the study period, 787 patients underwent KT, of whom 152 (19.3%) developed 356 UTI episodes. The most common micro-organisms wereEscherichia coli (165/356; 46.3%) and Klebsiella pneumoniae (101/356; 28.4%). Multidrug-resistant micro-organisms were isolated in 161 UTIs (45.2%). Risk factors for rUTI were diabetic nephropathy as the cause of end-stage renal disease (P = 0.02), UTI in first 180 days after KT (P = 0.04), anatomic alteration of the urinary tract at UTI diagnosis (P = 0.004) and length of time to effective therapy (P = 0.002); UTI treatment duration according to institutional protocol (P = 0.04) was the only protective factor identified.
Appropriate therapy duration has an impact on rUTI prevention after KT.
肾移植(KT)后常发生复发性尿路感染(rUTI),但其最佳治疗方法仍不明确。本研究旨在确定 rUTI 的危险因素,并验证 KT 后尿路感染和 rUTI 治疗方案。
这是一项回顾性队列研究,纳入 2013 年 1 月至 2016 年 7 月期间接受 KT 的患者。患者从 KT 之日起随访至移植物丢失、死亡或随访结束(2018 年 12 月 31 日)。我们分析了所有有症状的 UTI 发作。主要结局指标是 KT 后的 rUTI。在多水平方法中,对每个发作进行分析;在远端水平考虑患者特征,在近端水平考虑 UTI 特征。采用 Cox 回归进行单变量和多变量分析。采用倾向评分调整耐碳青霉烯类肠杆菌科细菌(CR-EB)患者的风险。
研究期间,787 例患者接受 KT,其中 152 例(19.3%)发生 356 次 UTI 发作。最常见的微生物是大肠埃希菌(165/356;46.3%)和肺炎克雷伯菌(101/356;28.4%)。161 次 UTI 分离出多药耐药微生物。rUTI 的危险因素是糖尿病肾病作为终末期肾病的病因(P = 0.02)、KT 后 180 天内发生 UTI(P = 0.04)、UTI 诊断时尿路解剖结构改变(P = 0.004)和有效治疗时间(P = 0.002);根据机构方案确定的 UTI 治疗持续时间(P = 0.04)是唯一确定的保护因素。
适当的治疗持续时间对 KT 后 rUTI 的预防有影响。